• Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system – the Stavanger experience 

      Viste, Eirik; Vinje, Cathrine Alvær; Lid, Torgeir Gilje; Skeie, Svein; Evjen-Olsen, Øystein; Nordström, Tobias; Thorsen, Olav; Gilje, Bjørnar; Janssen, Emiel; Kjosavik, Svein Reidar (Journal article; Peer reviewed, 2020)
      Objective To describe early experience of replacing PSA with Stockholm3 for detection of prostate cancer in primary care. Design and methods Longitudinal observations, comparing outcome measures before and after the ...
    • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 

      Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Journal article; Peer reviewed, 2020)
      Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic ...
    • The role of microRNAs as predictors of response to tamoxifen treatment in breast cancer patients 

      Egeland, Nina; Lunde, Siri; Jonsdottir, Kristin; Lende, Tone Hoel; Cronin-Fenton, Deirdre P.; Gilje, Bjørnar; Janssen, Emilius Adrianus Maria; Søiland, Håvard (Peer reviewed; Journal article, 2015-10-14)
      Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen ...